|
Now clinical treatment for non-small cell lung cancer is development,such as surgery, radiotherapy, and chemotherapy are still insufficient.molecular targeted therapy have become one of the most important options,not only for its tolerability, but also for higher response rate and longersurvival obtained when comparing with conventional chemotherapy.However, the efficacy of molecular targeted drugs is limited by eitherprimary or acquired resistance after therapy. Some molecular targeted drugscombined with radiotherapy can increase the sensitivity of radiotherapy，enhance efficiency. The emergence of new target to bring more choices forclinical treatment, which widen the understanding of personalized therapy.
|